Since these mutations increase substantially PD risk, targeted investigations of non-manifesting mutation carriers of LRRK2, PINK1, GBA, and SNCA provide a unique opportunity to understand OD in PD. This evidence concerns the gene LRRK2 and osteochondritis dissecans.